GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kairos Pharma KAPA · USD

N/A · US listing · 🇺🇸 United States

Compare

0.51

+3.48%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Kairos Pharma

From its filings with the US Securities and Exchange Commission

SEC filings

Kairos Pharma is based in Los Angeles, California and is incorporated in Delaware. Its shares trade on NYSE under the ticker KAPA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $5.4m. At that date it held total assets of $6.5m and shareholders' equity of $6.3m.

Read the filing on SEC.gov ↗

Company facts

Sector
N/A
Industry
N/A
Listed since
16 Sept 2024
Head office
2355 WESTWOOD BLVD. #139, LOS ANGELES, CA, 90064
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Dr. John YuChairman of the Board, Chief Executive Officer$85,741
  • Mr. Douglas SamuelsonChief Financial Officer$137,657
  • Dr. Neil BhowmickChief Scientific Officer$63,755
  • Dr. Ramachandran MuraliVice President - Research and Development$57,892
  • Dr. Hyun BaeIndependent Director$39,183
  • Dr. Hansoo KeyoungIndependent Director$42,100
  • Dr. Rahul SinghviIndependent Director$52,822

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Kairos Pharma Ltd develops five clinical-stage drug candidates targeting prostate cancer and lung cancer.
  • Enviro Therapeutics subsidiary provides two therapeutic agents for anti-tumor response in cancer therapies.
  • Kairos Pharma's product portfolio includes KROS 101, 102, 201, 301, 401, ENV 105, and 205.

Weaknesses

  • Kairos Pharma Ltd is a clinical-stage biopharmaceutical company with no approved products.
  • Kairos Pharma's products are still in pre-clinical or clinical trials without market approval.
  • The company has no revenue from commercialized products as it focuses on development.

Opportunities

  • Kairos Pharma's clinical-stage drug candidates address immune suppression in cancer treatments.
  • Enviro Therapeutics' technology targets CD105 for treating diseases by depleting mitochondrial DNA.
  • The company can expand its product portfolio through additional licensing agreements.

Threats

  • Kairos Pharma's clinical-stage drugs face regulatory approval risks in the US market.
  • The company's reliance on pre-clinical and clinical trials increases development costs and timelines.
  • Kairos Pharma's focus on cancer treatments exposes it to competition in the oncology sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.